SEC Form 4 · accession 0001178913-18-001598
Foamix Pharmaceuticals Ltd. · FOMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Domzalski
Officer — CEO · Director
Period of report
May 8, 2018
Accepted (ET)
May 10, 2018 · 5:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001606645
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2,F3 | May 8, 2018 | A | 23,396 | $0.00 | D | 163,150 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionsF4,F1,F5 | $5.06 | May 8, 2018 | A | 70,187 | A | — | Feb 27, 2028 | Ordinary Shares | 70,187 | 70,187 | D |
Explanation of responses
- F1The equity incentive grants were approved by the Issuer's board of directors on the recommendation of a committee of the board on February 27, 2019, subject to shareholder approval as required under the Israeli Companies Law. The Issuer's shareholders approved the equity incentive grants on May 8, 2018.
- F2The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022.
- F3This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
- F4Each option represents a contingent right to purchase one ordinary share of the issuer.
- F5The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022.